Johnson & Johnson Stock , JNJ

256.44 +0.56 +0.22%
03:59:59 PM EDT 7/31/2026 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 07/31/2026 the closing price of the Johnson & Johnson share was $255.88 on BTT. Compared to the opening price on Friday 07/31/2026 on BTT of $260.89, this is a drop of 1.96%. Johnson & Johnson's market capitalization is $498.71 B by 2.41 B shares outstanding.
Is Johnson & Johnson stock a Buy, Sell or Hold? Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 45 buy ratings, 32 hold ratings, and 0 sell ratings.
What was the 52-week low for Johnson & Johnson stock? The low in the last 52 weeks of Johnson & Johnson stock was 164.24. According to the current price, Johnson & Johnson is 156.14% away from the 52-week low.
What was the 52-week high for Johnson & Johnson stock? The high in the last 52 weeks of Johnson & Johnson stock was 274.89. According to the current price, Johnson & Johnson is 93.29% away from the 52-week high.
What are analysts forecasts for Johnson & Johnson stock? The 77 analysts offering price forecasts for Johnson & Johnson have a median target of 213.52, with a high estimate of 298.00 and a low estimate of 152.00. The median estimate represents a 120.10 difference from the last price of 256.44.

Johnson Johnson Stock Snapshot

255.85
Bid
1.00
Bid Size
269.52
Ask
100.00
Ask Size
7/31/2026
Date
3:59 PM
Time
285,229.00
Volume
255.88
Prev. Close
256.68
Open
617.78 B
Market Cap in USD
2.41 B
Number of Shares
2.41 B
Total Number of Shares
253.34
Day Low
258.48
Day High
256.44
164.24
52 Week Low
274.89
52 Week High
256.44
5.14
Dividend in USD
2.48
Dividend Yield
18.82
P/E Ratio
99.87
Free Float in %
11.03
EPS in USD
33.86
Book Value per Share in USD
10.10
Cash Flow per Share in USD

Historical Prices for Johnson & Johnson

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Johnson & Johnson Analyst Data

Total Analysts: 77
Buy Ratings: 45 Neutral Ratings: 32 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 152.00 Median: 213.52 Highest: 298.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Johnson & Johnson Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
07/17/26 Guggenheim
Maintained Buy $270
07/16/26 Raymond James Financial, Inc.
Maintained Buy $265
07/16/26 RBC Capital Markets
Maintained Buy $287
07/16/26 Wells Fargo & Co
Maintained Buy $272
07/16/26 Morgan Stanley
Maintained Buy $294
07/13/26 RBC Capital Markets
Maintained Buy $287
07/10/26 Bank of America Merrill Lynch
Maintained Hold $263
07/08/26 Morgan Stanley
Maintained Buy $284
07/08/26 Citigroup Corp.
Maintained Buy $298
06/26/26 Guggenheim
Maintained Buy $270
04/15/26 Barclays Capital
Maintained Hold $255
04/15/26 Stifel, Nicolaus & Co., Inc.
Maintained Buy $250
04/15/26 Wells Fargo & Co
Maintained Buy $263
04/10/26 Morgan Stanley
Maintained Buy $267
03/30/26 RBC Capital Markets
Maintained Buy $255
03/19/26 Barclays Capital
Maintained Hold $234
03/17/26 HSBC
Maintained Buy $280
03/11/26 Citigroup Corp.
Maintained Buy $274
03/05/26 J.P. Morgan
Maintained Hold $250
02/03/26 RBC Capital Markets
Maintained Buy $255
01/28/26 Morgan Stanley
Upgraded to Buy $262
01/23/26 Guggenheim
Maintained Buy $240
01/22/26 Citigroup Corp.
Maintained Buy $250
01/22/26 Bank of America Merrill Lynch
Maintained Hold $221
01/22/26 Morgan Stanley
Maintained Hold $200
01/22/26 Wells Fargo & Co
Maintained Buy $240
01/22/26 Stifel, Nicolaus & Co., Inc.
Maintained Buy $220
01/09/26 Bernstein
Maintained Hold $208
12/30/25 Barclays Capital
Maintained Hold $217
12/19/25 Goldman Sachs
Maintained Buy $240
12/15/25 Bank of America Merrill Lynch
Maintained Hold $220
12/12/25 Morgan Stanley
Maintained Hold $197
12/11/25 Citigroup Corp.
Maintained Buy $232
12/11/25 RBC Capital Markets
Maintained Buy $230
12/05/25 Guggenheim
Maintained Buy $227
12/02/25 Barclays Capital
Maintained Hold $197
10/15/25 Citigroup Corp.
Maintained Buy $215
10/15/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $190
10/15/25 Raymond James Financial, Inc.
Maintained Buy $209
10/15/25 Morgan Stanley
Maintained Hold $190
10/15/25 Bank of America Merrill Lynch
Maintained Hold $204
10/14/25 UBS
Maintained Buy $214
10/10/25 Morgan Stanley
Maintained Hold $178
10/09/25 Goldman Sachs
Maintained Buy $212
10/07/25 Citigroup Corp.
Maintained Buy $213
10/06/25 Bernstein
Maintained Hold $193
10/03/25 Bank of America Merrill Lynch
Maintained Hold $198
10/03/25 Wells Fargo & Co
Upgraded to Buy $212
09/23/25 Guggenheim
Upgraded to Buy $206
09/16/25 J.P. Morgan
Maintained Hold $200

Johnson & Johnson Estimates* in USD

  2026 2027 2028 2029 2030
Revenue 101,272 108,631 117,035 124,853 134,042
Dividend 5.38 5.63 5.75 5.97 6.22
Dividend Yield (in %) 2.10 % 2.20 % 2.24 % 2.33 % 2.43 %
EPS 11.65 12.81 14.26 16.14 17.95
P/E Ratio 22.00 20.02 17.99 15.89 14.28
EBIT 33,502 36,773 40,693 46,295 51,540
EBITDA 38,219 41,310 44,700 48,088 49,161
Net Profit 28,416 31,087 34,740 39,064 43,443
Net Profit Adjusted 28,416 31,087 34,740 39,064 43,443
Pre-Tax Profit 34,408 37,801 42,311 47,536 52,900
Pre-Tax Profit Reported 28,552 31,716 38,881 36,902 39,473
EPS (Non-GAAP) ex. SOE 11.76 12.75 14.00 15.88 -
EPS (GAAP) 10.64 11.74 12.94 12.48 13.35
Gross Income 73,294 79,070 85,078 92,011 98,847
Cash Flow from Investing -6,323 -6,156 -5,989 -6,165 -5,915
Cash Flow from Operations 30,547 34,118 37,709 42,427 46,238
Cash Flow from Financing - - - - -
Cash Flow per Share 12.62 13.85 15.80 - -
Free Cash Flow 25,537 28,192 29,879 34,543 -
Free Cash Flow per Share - - - - -
Book Value per Share 37.04 41.67 47.37 41.89 44.96
Net Debt 20,024 7,517 -10,418 -24,030 -
Research & Development Exp. 15,423 16,452 16,680 17,439 18,298
Capital Expenditure 4,881 5,019 5,213 4,846 4,415
Selling, General & Admin. Exp. 25,001 26,092 27,292 28,524 29,965
Shareholder’s Equity 91,927 106,902 123,946 162,741 191,470
Total Assets 214,803 229,958 247,771 285,031 314,442
  Previous Quarter
ending 06/30/26 		Current Quarter
ending 09/30/26 		Next Quarter
ending 12/31/26 		Current Year
ending 12/31/26 		Next Year
ending 12/31/27
Earnings Estimates
No. of Analysts - 15 16 20 21
Average Estimate - 3.021 USD 3.021 USD 11.653 USD 12.811 USD
Year Ago - 2.139 USD 2.125 USD 11.134 USD -
Publish Date - 10/20/2026 1/26/2027 - -
Revenue Estimates
No. of Analysts - 15 15 20 20
Average Estimate - 25,322 USD 26,495 USD 101,272 USD 108,631 USD
Year Ago - 23,992 USD 24,562 USD 94,178 USD -
Publish Date - 10/20/2026 1/26/2027 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2025 2024 2023 2022 2021 2020 2019
Sales 94,178.00 88,819.00 85,152.00 95,015.00 93,758.00 82,572.00 82,113.00
Change of sales in % 6.03 4.31 -10.38 1.34 13.55 0.56 0.71
Gross profit on sales 64,626.00 60,957.00 58,722.00 64,297.00 63,884.00 54,574.00 54,978.00
Gross profit on sales change in % 6.02 3.81 -8.67 0.65 17.06 -0.73 1.16
Operating income 26,124.00 20,823.00 22,162.00 24,780.00 24,481.00 20,468.00 21,550.00
Operating income change in % 25.46 -6.04 -10.56 1.22 19.61 -5.02 1.40
Income before tax 32,581.00 16,687.00 15,062.00 21,725.00 22,776.00 16,497.00 17,328.00
Income before tax change in % 95.25 10.79 -30.67 -4.61 38.06 -4.80 -3.73
Income after tax 26,804.00 14,066.00 13,326.00 17,941.00 20,878.00 14,714.00 15,119.00
Income after tax change in % 90.56 5.55 -25.72 -14.07 41.89 -2.68 -1.16

Balance Sheet in Mio. USD

2025 2024 2023 2022 2021 2020 2019
Total liabilities 117,666.00 108,614.00 98,784.00 110,574.00 107,995.00 111,616.00 98,257.00
Long-term liabilities per share 26.39 24.22 21.81 20.96 23.88 26.26 23.66
Equity 81,544.00 71,490.00 68,774.00 76,804.00 74,023.00 63,278.00 59,471.00
Equity change in % 14.06 3.95 -10.46 3.76 16.98 6.40 -0.47
Balance sheet total 199,210.00 180,104.00 167,558.00 187,378.00 182,018.00 174,894.00 157,728.00
Balance sheet total change in % 10.61 7.49 -10.58 2.94 4.07 10.88 3.12

Key Data in USD

2025 2024 2023 2022 2021 2020 2019
Sales per share 38.77 36.56 33.26 35.67 35.06 30.92 30.59
P/E ratio (year end quote, basic EPS) 18.82 25.05 28.32 26.23 21.91 28.57 25.88
P/E ratio (year end quote, diluted EPS) 18.82 25.05 28.32 26.23 21.91 28.57 25.88
Dividend yield in % 2.48 3.39 3.00 2.52 2.45 2.53 2.57
Equity ratio in % 40.93 39.69 41.04 40.99 40.67 36.18 37.70
Debt ratio in % 59.07 60.31 58.96 59.01 59.33 63.82 62.30

Johnson & Johnson Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Broadhurst Vanessa 07/19/2026 23,054.00 23,003.00 251.27 Sell No
Broadhurst Vanessa 07/19/2026 11,129.00 34,132.00 129.51 Buy No
Broadhurst Vanessa 07/19/2026 11,925.00 46,057.00 131.94 Buy No
Wengel Kathryn E 06/10/2026 10,000.00 114,287.87 241.15 Sell No
Wengel Kathryn E 06/10/2026 10,000.00 124,287.87 115.67 Buy No
REED JOHN C 04/30/2026 11,002.00 24,911.00 229.85 Sell No
REED JOHN C 04/30/2026 25,255.00 35,913.00 n/a Buy No
Schmid Timothy 02/19/2026 1,322.00 25,447.00 245.66 Sell No
Swanson James D. 02/16/2026 20,521.00 25,698.13 242.70 Sell No
Broadhurst Vanessa 02/16/2026 6,197.00 23,003.00 243.39 Sell No
REED JOHN C 02/16/2026 2,283.00 10,658.00 243.00 Sell No
REED JOHN C 02/16/2026 29,927.00 12,941.00 243.00 Sell No
REED JOHN C 02/16/2026 21,721.00 12,941.00 243.00 Sell No
Swanson James D. 02/16/2026 20,521.00 46,219.13 164.62 Buy No
REED JOHN C 02/16/2026 29,927.00 42,868.00 156.15 Buy No
REED JOHN C 02/16/2026 21,721.00 34,662.00 157.92 Buy No
Decker Robert J 02/14/2026 95.00 23,682.00 243.45 Sell No
Decker Robert J 02/14/2026 94.00 23,433.00 243.45 Sell No
Swanson James D. 02/14/2026 309.00 25,698.13 243.45 Sell No
Swanson James D. 02/14/2026 214.00 25,298.13 243.45 Sell No
Broadhurst Vanessa 02/14/2026 270.00 29,200.00 243.45 Sell No
Broadhurst Vanessa 02/14/2026 252.00 28,944.00 243.45 Sell No
REED JOHN C 02/14/2026 528.00 12,941.00 243.45 Sell No
REED JOHN C 02/14/2026 385.00 11,622.00 243.45 Sell No
Decker Robert J 02/14/2026 344.00 23,777.00 n/a Buy No

Johnson Johnson Dividend Calendar

Date Name Dividend *yield Currency
2025 Johnson & Johnson 5.14 2.48 USD
2024 Johnson & Johnson 4.91 3.39 USD
2023 Johnson & Johnson 4.70 3.00 USD
2022 Johnson & Johnson 4.45 2.52 USD
2021 Johnson & Johnson 4.19 2.45 USD
2020 Johnson & Johnson 3.98 2.53 USD
2019 Johnson & Johnson 3.75 2.57 USD
2018 Johnson & Johnson 3.54 2.78 USD
2017 Johnson & Johnson 3.32 2.38 USD
2016 Johnson & Johnson 3.15 2.73 USD
2015 Johnson & Johnson 2.95 2.87 USD
2014 Johnson & Johnson 2.76 2.63 USD
2013 Johnson & Johnson 2.59 2.80 USD
2012 Johnson & Johnson 2.40 3.45 USD
2011 Johnson & Johnson 2.25 3.43 USD
2010 Johnson & Johnson 2.11 3.41 USD
2009 Johnson & Johnson 1.93 3.00 USD
2008 Johnson & Johnson 1.79 3.06 USD
2007 Johnson & Johnson 1.62 2.43 USD
2006 Johnson & Johnson 1.46 2.21 USD
2005 Johnson & Johnson 1.27 2.11 USD
2004 Johnson & Johnson 1.09 1.72 USD
2003 Johnson & Johnson 0.92 1.82 USD
2002 Johnson & Johnson 0.79 1.47 USD
2001 Johnson & Johnson 0.70 1.17 USD
2000 Johnson & Johnson 0.62 1.18 USD
1999 Johnson & Johnson 0.55 1.18 USD
*Yield of the Respective Date

Johnson Johnson Calendar

Event Estimate Info Date
Earnings Report 3.021 USD Q3 2026 Earnings Release 10/20/2026
Earnings Report 3.021 USD Q4 2026 Earnings Release 01/26/2027
Earnings Report 2.897 USD Q1 2027 Earnings Release 04/20/2027
Earnings Report 3.123 USD Q2 2027 Earnings Release 07/21/2027

Johnson Johnson Past Events

Event Actual EPS Info Date
Earnings Report 2.270 USD Q2 2026 Earnings Release 07/15/2026
Annual General Meeting 11.030 USD Annual General Meeting 04/23/2026
Earnings Report 2.140 USD Q1 2026 Earnings Release 04/14/2026
Earnings Report 2.100 USD Q4 2025 Earnings Release 01/21/2026
Earnings Report 2.120 USD Q3 2025 Earnings Release 10/14/2025
Earnings Report 2.290 USD Q2 2025 Earnings Release 07/16/2025
Annual General Meeting 5.790 USD Annual General Meeting 04/24/2025
Earnings Report 4.540 USD Q1 2025 Earnings Release 04/15/2025
Earnings Report 1.410 USD Q4 2024 Earnings Release 01/22/2025
Earnings Report 1.110 USD Q3 2024 Earnings Release 10/15/2024
Earnings Report 1.930 USD Q2 2024 Earnings Release 07/17/2024
Annual General Meeting 13.720 USD Annual General Meeting 04/25/2024
Earnings Report 1.340 USD Q1 2024 Earnings Release 04/16/2024
Earnings Report 1.670 USD Q4 2023 Earnings Release 01/23/2024
Earnings Report 1.690 USD Q3 2023 Earnings Release 10/17/2023
Earnings Report 1.960 USD Q2 2023 Earnings Release 07/20/2023
Annual General Meeting 6.730 USD Annual General Meeting 04/27/2023
Earnings Report -0.030 USD Q1 2023 Earnings Release 04/18/2023
Earnings Report 1.330 USD Q4 2022 Earnings Release 01/24/2023
Earnings Report 1.680 USD Q3 2022 Earnings Release 10/18/2022
Earnings Report 1.800 USD Q2 2022 Earnings Release 07/19/2022
Annual General Meeting 7.810 USD Annual General Meeting 04/28/2022
Earnings Report 1.930 USD Q1 2022 Earnings Release 04/19/2022
Earnings Report 1.770 USD Q4 2021 Earnings Release 01/25/2022

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Johnson & Johnson Management

Name Job
Joaquin Duato Chairman & Chief Executive Officer
Robert J. Decker Chief Accounting Officer & Controller
Ronald A. Kapusta Chief Accounting Officer & Controller
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Kristen Blair Mulholland Chief Human Resources Officer & Executive VP
James D. Swanson Chief Information Officer & Executive VP
Elizabeth Forminard Chief Legal Officer & Executive Vice President
Penny M. Heaton Chief Medical Officer
Kathryn E. Wengel Chief Technical Operations & Risk Officer
George Davy Director-Global Human Resources
Jonathan Sheh Director-Workplace Experience
Jennifer L. Taubert EVP & Worldwide Chairman-Innovative Medicine
Timothy Schmid Executive Vice President & Chairman-Worldwide
John C. Reed Executive Vice President-Innovative Medicine
Jessica Moore Group Chief Financial Officer-Innovative Medicine
Mark B. McClellan Independent Director
Mark Alan Weinberger Independent Director
Hubert Joly Independent Director
John George Morikis Independent Director
Daniel E. Pinto Independent Director
Jennifer A. Doudna Independent Director
Paula A. Johnson Independent Director
Mary C. Beckerle Independent Director
Eugene A. Woods Independent Director
Nadja Y. West Independent Director
Marillyn A. Hewson Lead Independent Director
Thomas J. Spellman Secretary
Marc Larkins Secretary & Vice President-Worldwide Governance
Sid Jain VP-Global Development Data Science
Ryan Koors Vice President-Investor Relations